PRAX earnings analysis
What we found in PRAX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Praxis Precision Medicines, Inc. reported its Q1 2026 results with a substantial net loss of $92.6 million, driven by increased operating expenses, particularly in research and development. The company's ongoing evaluation of its product candidates remains critical for future profitability, hinged on successful clinical developments and regulatory approvals.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased Operating Expenses
- Total operating expenses rose to $105.9 million in Q1 2026 from $74.7 million in Q1 2025, an increase of $31.1 million.
- R&D Spending Up
- Research and development expenses increased by $17.2 million to $78.0 million in Q1 2026 compared to $60.8 million in Q1 2025.
- Cash Reserves Robust
- Cash, cash equivalents, and marketable securities stand strong at $1.4 billion as of March 31, 2026.
- Higher General and Admin Costs
- General and administrative expenses surged to $27.9 million in Q1 2026 from $13.9 million in Q1 2025, indicating a rise of $13.9 million.
- Positive NDA Submissions
- NDA applications for ulixacaltamide and relutrigine have been submitted and accepted for review, with respective PDUFA action dates of January 29, 2027 and September 27, 2026.
- Financing Activity Strong
- The company raised approximately $609.4 million in Q1 2026 through financing activities, a notable increase from $54.3 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Quarterly Loss
- The net loss for Q1 2026 was $92.6 million, significantly higher than the $69.3 million loss in Q1 2025.
- Lack of Revenue Generation
- Praxis has not yet generated any revenue from product sales since inception, relying solely on financing activities.
- Long Path to Profitability
- With no products on the market, there is uncertainty regarding the timeline and ability to achieve profitability.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PRAX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever